Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant HIV-1 clade B measles vaccine vector
- Development stage
- Phase 1
- Lead developer
- Institut Pasteur
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant HIV-1 clade B measles vaccine vector is an investigational viral vector vaccine developed by the Institut Pasteur for the prevention of HIV-1 infection. The vaccine utilizes the live-attenuated Schwarz strain of the measles virus (MV) as a delivery platform, which has been genetically engineered to express HIV-1 clade B antigens, typically including the Gag protein and segments of the Pol and Env proteins. By using the measles virus—a highly immunogenic vector with a proven safety profile in global pediatric vaccination—the vaccine aims to induce robust and long-lasting HIV-specific cellular (T-cell) and humoral (B-cell) immune responses. Clinical development has proceeded through Phase I trials (e.g., NCT00661154) to evaluate safety, reactogenicity, and immunogenicity in healthy adults.
- Other names
- HIV-1 clade B measles vaccineHIV1 clade B measles vaccineHIV 1 clade B measles vaccineMV-HIV vaccineSchwarz measles virus-HIV-1 clade B recombinant vaccine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasegp41 (Human immunodeficiency virus type 1 glycoprotein 41)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on recombinant HIV-1 clade B measles vaccine vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant HIV-1 clade B measles vaccine vector.